G
Gad Getz
Researcher at Broad Institute
Publications - 627
Citations - 309042
Gad Getz is an academic researcher from Broad Institute. The author has contributed to research in topics: Cancer & Biology. The author has an hindex of 189, co-authored 520 publications receiving 247560 citations. Previous affiliations of Gad Getz include University of Colorado Denver & University of California, San Diego.
Papers
More filters
Journal ArticleDOI
Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes
Bjoern Chapuy,Chip Stewart,Andrew Dunford,Jaegil Kim,Atanas Kamburov,Robert A. Redd,Michael S. Lawrence,Michael S. Lawrence,Margaretha G.M. Roemer,Amy Li,Marita Ziepert,Annette M. Staiger,Annette M. Staiger,Jeremiah Wala,Matthew D. Ducar,Ignaty Leshchiner,Ester Rheinbay,Amaro Taylor-Weiner,Caroline A. Coughlin,Julian M. Hess,Chandra Sekhar Pedamallu,Dimitri Livitz,Daniel Rosebrock,Mara Rosenberg,Adam Tracy,Heike Horn,Paul Van Hummelen,Andrew L. Feldman,Brian K. Link,Anne J. Novak,James R. Cerhan,Thomas M. Habermann,Reiner Siebert,Andreas Rosenwald,Aaron R. Thorner,Matthew Meyerson,Matthew Meyerson,Todd R. Golub,Todd R. Golub,Rameen Beroukhim,Rameen Beroukhim,Gerald Wulf,German Ott,Scott J. Rodig,Scott J. Rodig,Stefano Monti,Donna Neuberg,Markus Loeffler,Michael Pfreundschuh,Lorenz Trümper,Gad Getz,Gad Getz,Margaret A. Shipp +52 more
TL;DR: A comprehensive genetic analysis of 304 primary DLBCLs identified low-frequency alterations, captured recurrent mutations, somatic copy number alterations, and structural variants, and defined coordinate signatures in patients with available outcome data to provide a roadmap for an actionableDLBCL classification.
Journal ArticleDOI
Assessing the significance of chromosomal aberrations in cancer: Methodology and application to glioma
Rameen Beroukhim,Gad Getz,Leia Nghiemphu,Jordi Barretina,Teli Hsueh,David Linhart,Igor Vivanco,Jeffrey C. Lee,Julie H. Huang,Sethu Alexander,Jinyan Du,Tweeny R Kau,Roman K. Thomas,Kinjal Shah,Horacio Soto,Sven Perner,John R. Prensner,Ralph M. Debiasi,Francesca Demichelis,Charlie Hatton,Mark A. Rubin,Levi A. Garraway,Stan F. Nelson,Linda M. Liau,Paul S. Mischel,Timothy F. Cloughesy,Matthew Meyerson,Todd Golub,Eric S. Lander,Ingo K. Mellinghoff,William R. Sellers +30 more
TL;DR: A systematic method, called Genomic Identification of Significant Targets in Cancer (GISTIC), designed for analyzing chromosomal aberrations in cancer, is used to study gliomas and the results support the feasibility and utility of systematic characterization of the cancer genome.
Journal ArticleDOI
SF3B1 and Other Novel Cancer Genes in Chronic Lymphocytic Leukemia
Lili Wang,Michael S. Lawrence,Youzhong Wan,Petar Stojanov,Carrie Sougnez,Kristen E. Stevenson,Lillian Werner,Andrey Sivachenko,David S. DeLuca,Li Zhang,Wandi Zhang,Alexander R. Vartanov,Stacey M. Fernandes,Natalie R. Goldstein,Eric G. Folco,Kristian Cibulskis,Bethany Tesar,Quinlan L. Sievers,Erica Shefler,Stacey Gabriel,Nir Hacohen,Robin Reed,Matthew Meyerson,Todd R. Golub,Eric S. Lander,Donna Neuberg,Jennifer R. Brown,Gad Getz,Catherine J. Wu +28 more
TL;DR: This study defines the landscape of somatic mutations in chronic lymphocytic leukemia and highlights pre-mRNA splicing as a critical cellular process contributing to chronic lymphocrytic leukemia.
Journal ArticleDOI
An APOBEC cytidine deaminase mutagenesis pattern is widespread in human cancers
Steven A. Roberts,Michael S. Lawrence,Leszek J. Klimczak,Sara A. Grimm,David C. Fargo,Petar Stojanov,Adam Kiezun,Gregory V. Kryukov,Gregory V. Kryukov,Scott L. Carter,Gordon Saksena,Shawn F. Harris,Ruchir R. Shah,Michael A. Resnick,Gad Getz,Gad Getz,Dmitry A. Gordenin +16 more
TL;DR: It is shown that throughout cancer genomes APOBEC-mediated mutagenesis is pervasive and correlates withAPOBEC mRNA levels, and that ubiquitous APOBec-mediated Mutagenesis are carcinogenic.
Journal ArticleDOI
The genetic landscape of high-risk neuroblastoma
Trevor J. Pugh,Olena Morozova,Edward F. Attiyeh,Edward F. Attiyeh,Shahab Asgharzadeh,Shahab Asgharzadeh,Jun S. Wei,Daniel Auclair,Scott L. Carter,Kristian Cibulskis,Megan Hanna,Megan Hanna,Adam Kiezun,Jaegil Kim,Michael S. Lawrence,Lee Lichenstein,Aaron McKenna,Chandra Sekhar Pedamallu,Chandra Sekhar Pedamallu,Alex H. Ramos,Alex H. Ramos,Erica Shefler,Andrey Sivachenko,Carrie Sougnez,Chip Stewart,Adrian Ally,Inanc Birol,Readman Chiu,Richard Corbett,Martin Hirst,Shaun D. Jackman,Baljit Kamoh,Alireza Hadj Khodabakshi,Martin Krzywinski,Allan Lo,Richard A. Moore,Karen Mungall,Jenny Q. Qian,Angela Tam,Nina Thiessen,Yongjun Zhao,Kristina A. Cole,Kristina A. Cole,Maura Diamond,Maura Diamond,Sharon J. Diskin,Sharon J. Diskin,Yael P. Mosse,Yael P. Mosse,Andrew Wood,Andrew Wood,Lingyun Ji,Lingyun Ji,Richard Sposto,Richard Sposto,Thomas C. Badgett,Wendy B. London,Yvonne Moyer,Yvonne Moyer,Julie M. Gastier-Foster,Julie M. Gastier-Foster,Malcolm A. Smith,Jaime M. Guidry Auvil,Daniela S. Gerhard,Michael D. Hogarty,Michael D. Hogarty,Steven J.M. Jones,Eric S. Lander,Stacey Gabriel,Gad Getz,Robert C. Seeger,Robert C. Seeger,Javed Khan,Marco A. Marra,Matthew Meyerson,Matthew Meyerson,John M. Maris +76 more
TL;DR: The authors reported a low median exonic mutation frequency of 0.60 per Mb (0.48 nonsilent) and notably few recurrently mutated genes in high-risk neuroblastoma.